A new study linking higher pre‑conception vitamin B12 levels to a 66 % lower predicted risk of birth defects has been published in the Annals of Internal Medicine and reported by Euronews on 1 September 2026.

Study design and key findings

The research, conducted by scientists at Fudan University in China, followed a prospective cohort of more than 3,000 couples who provided blood samples up to four months before conception. In addition, 17,765 women were tested at four months’ gestation or earlier, allowing the investigators to compare pre‑conception nutrient status with outcomes measured later in pregnancy.

Outcome measurement focused on the predicted prevalence of birth defects – a composite of live‑birth anomalies, stillbirths and fetal abnormalities – expressed as cases per 1,000 pregnancies. The authors reported that mothers in the highest quartile of vitamin B12 concentration had a predicted prevalence of 16.2 cases per 1,000 pregnancies, compared with 49.6 cases per 1,000 pregnancies for those in the lowest quartile. This difference corresponds to a relative reduction of 66 % when the highest‑B12 group is compared with the lowest‑B12 group.

Fathers showed a similar direction of association, but the reduction in predicted birth‑defect prevalence was described as “smaller” and no precise figure was provided. The study also noted that mothers with adequate red‑blood‑cell folate (vitamin B9) in early pregnancy displayed a lower predicted prevalence of birth defects, suggesting a possible synergistic effect of multiple micronutrients.

Potential impact on European pre‑conception nutrition guidance

The timing of the publication – coinciding with renewed European Commission interest in revising nutrition recommendations for prospective parents – makes the findings particularly salient. If the association holds in broader populations, public‑health campaigns could emphasise vitamin B12‑rich foods such as poultry, meat, fish and dairy products for both men and women planning a pregnancy.

European health agencies typically base guideline revisions on a body of evidence rather than a single study. Nonetheless, the magnitude of the observed reduction – from 49.6 to 16.2 cases per 1,000 pregnancies – provides a concrete figure that policymakers can use when modelling potential public‑health gains. For every 1,000 pregnancies, the study suggests that improving maternal B12 status could prevent roughly 33 birth‑defect cases, assuming the association is causal and applicable to European cohorts.

It is worth noting that the study population was recruited in China, and dietary patterns, baseline B12 status and genetic factors may differ from those in Europe. The authors themselves did not claim that the results are directly transferable, and the Euronews report does not present any European replication data.

Broader evidence on vitamin B12 and child outcomes

Beyond the immediate birth‑defect risk, the packet references a 2026 systematic review of 22 studies that linked adequate maternal B12 status to better child cognitive outcomes, including language, memory and overall performance. While the review does not quantify the effect size, its inclusion underscores a growing consensus that pre‑conception B12 status may influence both structural and functional aspects of child development.

Combined with the new cohort data, the systematic review suggests a two‑fold public‑health argument: reducing severe congenital anomalies and supporting optimal neurodevelopment. Both outcomes are central to European health‑economic planning, given the long‑term costs associated with disability and special‑education needs.

Uncertainties and next steps

Several uncertainties remain. First, the study’s predicted prevalence figures are modelled estimates rather than observed incidence rates; the methodology for prediction is not detailed in the Euronews summary. Second, the paternal effect is described only qualitatively – the exact magnitude of risk reduction for fathers is unknown.

Second, the research relies on a single cohort from a single institution. Replication in diverse European settings would be needed to confirm external validity. Third, the study does not address potential confounders such as socioeconomic status, supplement use or co‑existing micronutrient deficiencies, although the systematic review does note that folate status also influences outcomes.

Finally, the primary peer‑reviewed article has not been accessed directly; the Euronews article is the sole source for the numerical claims. While Euronews is an established outlet, the lack of direct access to the journal article means that some methodological nuances may be missing from public reporting.

Future research could aim to (i) quantify the paternal B12 effect, (ii) test the association in European cohorts with differing dietary baselines, and (iii) evaluate whether supplementation before conception yields the same predictive benefit as naturally higher serum levels.

Predicted birth‑defect prevalence by maternal vitamin B12 level

Source: Euronews article citing the Annals of Internal Medicine study (2026).

What remains to be decided

European health authorities must weigh the new evidence against existing dietary data, supplement usage patterns and cost‑effectiveness analyses. If further studies corroborate the 66 % relative reduction, guidelines could shift from a focus on folate alone to a broader recommendation that includes adequate vitamin B12 intake for both prospective mothers and fathers.

Until such corroboration is available, the current findings should be presented as promising but provisional evidence. Public‑health messaging can acknowledge the association while emphasizing that a balanced diet remains the cornerstone of pre‑conception care.